Journal Publications

Export 133 results:
Author [ Title(Desc)] Type Year
Filters: Type is Journal Article  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
E
Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. Dolling D, Phillips A, Delpech V, Pillay D, Cane P, Crook A, Shepherd J, Fearnhill E, Hill T and Dunn D. HIV Med, 2012 May, Volume 13, Issue 5, p.309-14, (2012)
Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. . AIDS, 2007 May 11, Volume 21, Issue 8, p.1035-9, (2007)
F
Factors associated with short-term changes in HIV viral load and CD4(+) cell count in antiretroviral-naive individuals. . AIDS, 2014 Jun 01, Volume 28, Issue 9, p.1351-6, (2014)
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Pozniak A et al. Antivir Ther, 2008, Volume 13, Issue 5, p.675-85, (2008)
Factors influencing lopinavir and atazanavir plasma concentration. Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Gazzard B et al. J Antimicrob Chemother, 2010 Jan, Volume 65, Issue 1, p.129-37, (2010)
Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression. O'Connor J, Smith C, Lampe F, Hill T, Gompels M, Hay P, Chadwick D, Fisher M, Ainsworth J, Gilson R et al. AIDS, 2014 Mar 27, Volume 28, Issue 6, p.919-24, (2014)
Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. Barber T, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D and Dunn D. J Antimicrob Chemother, 2012 Apr, Volume 67, Issue 4, p.995-1000, (2012)
H
Hepatitis B, hepatitis C, and mortality among HIV-positive individuals. Thornton A, Jose S, Bhagani S, Chadwick D, Dunn D, Gilson R, Main J, Nelson M, Rodger A, Taylor C et al. AIDS, Volume 31, p.2525-32, (2017)
Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) study. Price H, Bansi L, Sabin C, Bhagani S, Burroughs A, Chadwick D, Dunn D, Fisher M, Main J, Nelson M et al. PLoS One, 2012, Volume 7, Issue 11, p.e49314, (2012)
HIV diagnosis at CD4 count above 500 cells/mm3 and progression to below 350 cells/mm3 without antiretroviral therapy. . J Acquir Immune Defic Syndr, 2007 Nov 01, Volume 46, Issue 3, p.275-8, (2007)
HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. Phillips A, Sabin C, Pillay D and Lundgren J. HIV Med, 2007 Nov, Volume 8, Issue 8, p.536-46, (2007)
HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Chilton D, Castro H, Lattimore S, Harrison L, Fearnhill E, Delpech V, Rice B, Pillay D and Dunn D. Antivir Ther, 2010, Volume 15, Issue 7, p.985-91, (2010)
HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysis. Dolling D, Dunn D, Geretti A and Sabin C. Clin Infect Dis, 2013 Jan, Volume 56, Issue 1, p.162-3, (2013)
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T et al. Eur J Neurol, 2011 Mar, Volume 18, Issue 3, p.527-34, (2011)
HLA B*5701 status, disease progression, and response to antiretroviral therapy. . AIDS, 2013 Oct 23, Volume 27, Issue 16, p.2587-92, (2013)
Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. Winston A, Stöhr W, Antinori A, Arenas-Pinto A, Llibre J, Amieva H, Cabié A, Williams I, Di Perri G, Tellez M et al. HIV Med, 2016 Jun, Volume 17, Issue 6, p.471-8, (2016)
I
The impact of HIV drug resistance testing on changes to treatment. Bansi L, Smith C, Phillips A, Kirk S, Geretti A, Johnson M, Mackie N, Post F, Gazzard B, Dunn D et al. AIDS, 2011 Mar 13, Volume 25, Issue 5, p.603-10, (2011)
The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. Mackie N, Dunn D, Dolling D, Garvey L, Harrison L, Fearnhill E, Tilston P, Sabin C and Geretti A. AIDS, 2013 Sep 10, Volume 27, Issue 14, p.2245-53, (2013)
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, Dunn D, Palfreeman A, Gilson R, Gazzard B et al. BMJ, 2011 Oct 11, Volume 343, p.d6016, (2011)
Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). Bansi L, Geretti A, Dunn D, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, Porter K, Phillips A et al. J Acquir Immune Defic Syndr, 2010 Apr, Volume 53, Issue 5, p.633-9, (2010)
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. May M, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, Hay P, Johnson M, Palfreeman A, Gilson R et al. AIDS, 2014 May 15, Volume 28, Issue 8, p.1193-202, (2014)
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. De Luca A, Flandre P, Dunn D, Zazzi M, Wensing A, Santoro M, Günthard H, Wittkop L, Kordossis T, García F et al. J Antimicrob Chemother, 2016 May, Volume 71, Issue 5, p.1352-60, (2016)